EU Approvals: J&J's Darzalex Steps Ahead With New Indication
Keytruda Cleared For First-Line Head & Neck Cancer
The European Commission has approved Johnson & Johnson’s/Genmab’s CD38-targeted MAb, daratumumab, and Merck & Co’s checkpoint inhibitor, pembrolizumab, in two first-line additional indications, in multiple myeloma and head and neck cancer, respectively.
You may also be interested in...
As it continues to build a presence in oncology, the company is starting a late-stage trial of GSK3359609 combined with Merck & Co's blockbuster Keytruda on the back of data presented at ESMO.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.